Optimized Pharmaceutical Formulation For The Treatment Of Inflammatory Conditions Of The Esophagus

Patent No. EP3086782 (titled "Optimized Pharmaceutical Formulation For The Treatment Of Inflammatory Conditions Of The Esophagus") was filed by Dr. Falk Pharma GmbH on Dec 18, 2014. The application was issued on Sep 26, 2018.

Patent Summary

Patent Family

Patent Family

Patent Oppositions (2)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
ADARE PHARMACEUTICALS US, L.P.Jun 26, 2019COOLEY UK
ELLODI PHARMACEUTICALS, L.P.Jun 26, 2019COOLEY UK

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP3086782

DR. FALK PHARMA GMBH
Application Number
EP14814872A
Filing Date
Dec 18, 2014
Status
Opposition Rejected
Aug 19, 2022
Publication Date
Sep 26, 2018